Lisdexamfetamine for the management of attention deficit hyperactivity disorder in adults

NHS Devon

Commissioning policy

The routine commissioning of lisdexamfetamine is accepted in Devon for the treatment of attention deficit hyperactivity disorder (ADHD) in adults who have failed to gain an adequate response to, or tolerate, methylphenidate. The Formulary Interface Group should include this in locally defined treatment recommendations.

Rationale for the decision

Lisdexamfetamine has been shown to be superior to placebo in improving ADHD symptoms in adults with ADHD. Direct comparisons of clinical effectiveness compared to other treatments licenced for the treatment of ADHD in adults (modified release methylphenidate and atomoxetine) are lacking. An indirect comparison found no significant difference between clinician rated ADHD symptom improvement when adult patients were treated with lisdexamfetamine or methylphenidate, but found lisdexamfetamine to be superior to atomoxetine.

Based on drug tariff costs prescribing of the lowest dose of lisdexamfetamine is more expensive than all but the highest doses of modified release methylphenidate, but is less expensive than higher doses of atomoxetine, and atomoxetine taken twice daily. The tariff costs of all other doses of lisdexamfetamine is more expensive than all doses of modified release methylphenidate and once daily atomoxetine.

Guidance notes on exceptionality

Where the circumstances of treatment for an individual patient do not meet the criteria described above exceptional funding can be sought. Individual cases will be reviewed by the appropriate panel of the ICB upon receipt of a completed application

from the patient's GP, consultant or clinician. Applications cannot be considered from patients personally.

Date of publication:	Version:
15.07.2021	Policy agreed by NHS Devon CCG Policy adopted by NHS Devon ICB on 01.07.2022